Indiana University raises $1.2 million for research at tailgate gala

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE INDIANA UNIVERSITY Melvin and Bren Simon Cancer Center raised nearly $1.2 million for cancer research at its fourth annual Chuckstrong Tailgate Gala.

Hosted by the Indianapolis Colts and head coach Chuck Pagano at the Indiana Farm Bureau Football Center, the gala raised the funds through corporate sponsorships, live and silent auctions, and the annual Chuckstrong Giving Challenge. The total includes $250,000 given by the Jim Irsay family, and $50,000 from the coach and his wife, Tina.

The record-setting amount also included $30,000 raised from 25 people who paid $1,200 each for the chance to catch a touchdown pass from quarterback Andrew Luck. In all, the Chuckstrong initiative has raised $3.7 million for cancer research at IU.

Top-level “touchdown” sponsors for the event were Anthem Blue Cross and Blue Shield, DairyChem, the Efroymson Family Fund, Huntington Bank, Lilly Oncology, Sol and Kay Raso, the Throgmartin family, the IU Simon Cancer Center, the IU School of Medicine, and Indiana Knitwear.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login